News

The FDA approved ivosidenib as the first targeted therapy to treat patients with previously treated IDH1-mutated cholangiocarcinoma.

While disparities exist in screening accessibility among the Hispanic/Latinx communities, the implementation of interventions have shown promising results in increased clinical trial participation.

The FDA’s priority review designation to abatacept may help to expand the stem cell donor pool by lowering acute graft-versus-host-disease risk in both children and adults, experts say.

The Food and Drug Administration approved adjuvant nivolumab to treat urothelial carcinoma in patients who are at high risk of recurrence after undergoing radical resection, irrespective of prior neoadjuvant chemotherapy, nodal involvement or PD-L1 status.

The new Oncology Medical Home standards represent a universal benchmark in a value-based model of oncology care.

Kelly L. Garvin, BSN, RN, OCN, discusses what changes she hopes to see in CAR T-Cell therapy treatment over the coming years.

The regulatory decision is based on findings from collective data from the dMMR endometrial cancer cohort A1 and the dMMR solid-tumor, non-endometrial cancer, cohort F of the ongoing phase 1 GARNET trial (NCT02715284).

Patients with non-small cell lung cancer driver mutations respond better to targeted treatments compared to chemotherapy, yet less than half of these patients receive next generation sequencing.

The continued development of KRAS G12C inhibitors for the treatment of non-small cell lung cancer shows that researchers are making breakthroughs in the treatment landscape.

The combination of pembrolizumab and lenvatinib has been FDA approved as a frontline therapy for the treatment of adult patients with advanced renal cell carcinoma.

African American, Asian, and Hispanic patients with limited-stage small cell lung cancer displayed superior survival outcomes compared with White patients, indicating that race might be linked with survival in this disease.

“More than 90% of serotonin receptors and serotonin is made in the gut.”

Treating patients with brentuximab vedotin in combination with doxorubicin, vinblastine, and dacarbazine with and without consolidative radiotherapy resulted in strong efficacy and encouraging tolerability in early-stage, unfavorable-risk Hodgkin lymphoma.

At 12 months, 97% patients treated with single infusions of cilta-cel had responded to the therapy.

Several cancer organizations signed a group statement calling for health care employers to mandate COVID-19 vaccinations for their employees.

The FDA has approved the first immunotherapy, pembrolizumab (Keytruda), to treat patients with high-risk early-stage triple-negative breast cancer.

Bristol Myers Squibb has chosen to withdraw the indication for single-agent nivolumab for patients with hepatocellular carcinoma with previous sorafenib treatment following a confirmatory phase 3 trial.

The International Association for the Study of Lung Cancer (IASLC) has published an updated consensus on the use of liquid biopsy in screening non-small cell lung cancer (NSCLC).

The FDA has granted a breakthrough therapy designation for venetoclax following interim results from the ongoing M15-531 trial.

The FDA has approved belumosudil for the treatment of patients aged 12 years and older with chronic graft-versus-host disease following failure of at least 2 prior lines of therapy.

The FDA approval of daratumumab plus hyaluronidase-fihj (Darzalex Faspro) plus pomalidomide and dexamethasone (Pd) was supported by data from the APOLLO trial.

Thomas G. Martin, MD, discusses the results of the IKEMA study and the future of isatuximab combination.

“For the first time, physicians can treat advanced urothelial cancer following treatment with a platinum-containing therapy and immunotherapy using an FDA-approved therapy that has demonstrated an OS benefit compared with chemotherapy.”

A trial evaluating melflufen in myeloma met its primary end point of progression free survival in the phase 3 OCEAN trial; however, overall survival was in favor of pomalidomide.

The FDA has offered support and encouragement for the development of paclitaxel plus encequidar.

The FDA has approved asparaginase erwinia chrysanthemi (recombinant)-rywn (Rylaze) as a complement of treatment for the most common childhood cancer.

Survival outcomes in the frontline treatment of patients with unresectable advanced or metastatic esophageal squamous cell carcinoma were improved when nivolumab was added alongside either ipilimumab or chemotherapy.

Consider options like prophylactic medications and optimal fluid administration when giving a 4-drug regimen to treat patients with multiple myeloma, one expert says.